Latest Articles

Publication Date
Preliminary Evaluation of Leuprorelin Acetate Microspheres Plus Levonorgestrel-Releasing Intrauterine System in Endometriosis: An Exploratory Study Focusing on BNIP3 and EPAC1 Expression.

This exploratory pilot study aimed to assess the preliminary clinical effects of leuprorelin acetate microspheres for injection [gonadotropin-releasing hormone agonist (GnRH-a)] combined with levonorgestrel-releasing intrauterine system (LNG-IUS) in treating endometriosis …

Published: May 14, 2026, midnight
[Investigation of pharmacological regimens combined with focused ultrasound ablation surgery for alleviating dysmenorrhea in extrinsic adenomyosis].

Objective: To investigate optimal long-term medication regimens combined with focused ultrasound ablation surgery (FUAS) for alleviating dysmenorrhea in patients with extrinsic adenomyosis. Methods: A retrospective research enrolled patients with extrinsic …

Published: April 29, 2026, midnight
Adenomyosis Pathophysiology, Diagnostic Advances, and Therapeutic Options.

Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of …

Published: April 2, 2026, midnight
Characteristics and Preoperative Management of Adolescent Patients With Pathology-Confirmed Endometriosis: A Multi-Institutional Study.

Endometriosis affects an estimated 25% to 75% of adolescent patients with chronic pelvic pain; the diagnosis is made surgically and treatment typically consists of hormone suppression and pain management strategies. …

Published: Jan. 19, 2026, midnight
Racial and Ethnic Differences in Risk for Hysterectomy Following Insertion of a Levonorgestrel-releasing Intra-uterine device: A Retrospective Cohort Study.

Evidence regarding risk for hysterectomy following treatment for benign gynecological conditions with a Levonorgestrel-releasing intrauterine device (LNG-IUD) is limited. We assess whether race and ethnicity are associated with hysterectomy risk …

Published: July 31, 2025, midnight
Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence.

To investigate the association between the duration of levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer risk in Korean women.

Published: March 13, 2025, midnight
Subdermal implants vs. levonorgestrel intrauterine devices outcomes in reproductive-aged women: a systematic review and meta-analysis.

We aimed to conduct a systematic review and meta-analysis comparing the outcomes of subdermal implants and levonorgestrel intrauterine system (LNG-IUS) in reproductive-aged women.

Published: March 11, 2025, midnight
Women's experience, satisfaction, and continuation with the levonogestrel-containing intrauterine system: A cross-sectional study.

The levonorgestrel-containing intrauterine system (LNG-IUS) is a safe, long-acting, reversible contraceptive method. This study aimed to examine women's experiences, satisfaction, and continuation with the levonorgestrel-containing intrauterine system. This cross-sectional study …

Published: Feb. 20, 2025, 12:15 a.m.
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).

Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other …

Published: Jan. 8, 2025, midnight
Cost-effectiveness of long-acting progestogens versus the combined oral contraceptives pill for preventing recurrence of endometriosis-related pain following surgery: an economic evaluation alongside the PRE-EMPT trial.

To evaluate the cost-effectiveness of long-acting progestogens (LAP), including levonorgestrel-releasing intrauterine system (LNG-IUS) and depot-medroxyprogesterone acetate (DMPA), compared with the combined oral contraceptives pill (COCP) in preventing recurrence of endometriosis-related …

Published: Dec. 9, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!